XOMA to Acquire 'Zombie' Biotech Generation Bio for $4.29 per Share

XOMA Royalty will acquire Generation Bio, a struggling gene therapy developer, for $4.29 per share, a price lower than Generation's closing price but includes contingent value rights. Generation Bio, which went public in 2020, has faced setbacks and lost most of its value, leading to the acquisition.